Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response

被引:13
作者
Cintolo, Jessica Anna [1 ]
Tchou, Julia [1 ]
Pryma, Daniel A. [2 ]
机构
[1] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
关键词
Breast cancer; PET; FDG PET; FLT-PET; FES-PET; PET/CT; Early treatment response; SENTINEL-NODE BIOPSY; TIME-OF-FLIGHT; STANDARDIZED UPTAKE VALUE; ESTROGEN-RECEPTOR STATUS; NEOADJUVANT CHEMOTHERAPY; FDG-PET/CT; CANCER PATIENTS; F-18-FDG PET/CT; PROGESTERONE-RECEPTOR; 3'-DEOXY-3'-F-18-FLUOROTHYMIDINE PET;
D O I
10.1007/s10549-013-2451-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Positron emission tomography (PET) is an imaging modality that using radiotracers, permits real-time dynamic monitoring of biologic processes such as cell metabolic behavior and proliferation, and has proven useful as a research tool for understanding tumor biology. While it does not have a well-defined role in breast cancer for the purposes of screening, diagnosis, or prognosis, emerging PET technologies and uses could expand the applications of PET in breast cancer. Positron emission mammography may provide an alternative adjunct imaging modality for the screening and diagnosis of high-risk patients unable to tolerate MRI. The development of radiotracers with the ability to measure hormonal activity could provide a non-invasive way to assess hormone receptor status and functionality. Finally, the role of PET technologies in monitoring early treatment response may prove particularly useful to research involving new therapeutic interventions.
引用
收藏
页码:331 / 346
页数:16
相关论文
共 140 条
[1]   Improvement in PET/CT Image Quality with a Combination of Point-Spread Function and Time-of-Flight in Relation to Reconstruction Parameters [J].
Akamatsu, Go ;
Ishikawa, Kaori ;
Mitsumoto, Katsuhiko ;
Taniguchi, Takafumi ;
Ohya, Nobuyoshi ;
Baba, Shingo ;
Abe, Koichiro ;
Sasaki, Masayuki .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (11) :1716-1722
[2]   Evaluation of brain tumors using dynamic 11C-methionine-PET [J].
Aki, Tatsuki ;
Nakayama, Noriyuki ;
Yonezawa, Shingo ;
Takenaka, Syunsuke ;
Miwa, Kazuhiro ;
Asano, Yoshitaka ;
Shinoda, Jun ;
Yano, Hirohito ;
Iwama, Toru .
JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (01) :115-122
[3]  
American Institute of Ultrasound in Medicine, 2009, J Ultrasound Med, V28, P105
[4]  
[Anonymous], 2012, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
[5]  
Avril Norbert, 1999, Clin Positron Imaging, V2, P261, DOI 10.1016/S1095-0397(99)00032-1
[6]   Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].
Bardou, VJ ;
Arpino, G ;
Elledge, RM ;
Osborne, CK ;
Clark, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979
[7]   Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation [J].
Barwick, Tara ;
Bencherif, Badreddine ;
Mountz, James M. ;
Avril, Norbert .
NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (12) :908-917
[8]  
Bassa P, 1996, J NUCL MED, V37, P931
[9]   Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters [J].
Basu, Sandip ;
Chen, Wengen ;
Tchou, Julia ;
Mavi, Ayse ;
Cermik, Tevfik ;
Czerniecki, Brian ;
Schnall, Mitchell ;
Alavi, Abass .
CANCER, 2008, 112 (05) :995-1000
[10]  
Bender H, 1997, ANTICANCER RES, V17, P1687